Accounting, budget, price.

Histogenics Cp Cmn (NASDAQ:HSGX) shares traded -5.08% down during most recent session to reach at the closing price of $0.56. The stock exchanged hands 2.61 Million shares versus average trading capacity of 1.96 Million shares, yielding a market cap of $26.7 Million. Wall Street analysts covering the stock are projecting that the stock will reach $3 within the next 52-weeks. The mean target projections are based on 5 opinions.

Taking a broader look brokerage firms’ analysts on the street with an expectant view have Histogenics Cp Cmn (NASDAQ:HSGX) high price target of $5 and with a conservative view have low price target of $1.5.

BTIG Research “Downgrades” Histogenics Cp Cmn (NASDAQ:HSGX) in a research note issued to investors on 9/06/18 to Neutral with price target of $0.

Additionally on 12/19/16 H.C. Wainwright “Initiates Coverage On” Histogenics Cp Cmn (NASDAQ:HSGX) to Buy setting price target at $3.5 and on 9/07/16 William Blair “Downgrades” the stock to Market Perform. Furthermore on 8/12/16 BTIG Research “Upgrades” the stock to Buy at $3.5.

On the other hand the company has Relative Strength Index (RSI 14) of 36.78 along with Average True Range (ATR 14) of 0.2, Consequently Histogenics Cp Cmn (NASDAQ:HSGX)’s weekly and monthly volatility is 34.80%, 16.74% respectively. The company’s beta value is at 1.49.

In terms of Buy, Sell or Hold recommendations, Histogenics Cp Cmn (NASDAQ:HSGX) has analysts’ mean recommendation of 2.2. This is according to a simplified 1 to 5 scale where 1 represents a Strong Buy and 5 a Strong Sell.

According to analysts Histogenics Cp Cmn (NASDAQ:HSGX)’s minimum EPS for the current quarter is at $-0.26 and can go high up to $-0.14. The consensus mean EPS for the current quarter is at $-0.2 derived from a total of 6 estimates from the analysts who have weighed in on projected earnings. However the company reported $-0.23 earnings per share for the same quarter during last year.

Previously Histogenics Cp Cmn (NASDAQ:HSGX) reported $-0.13 earnings per share (EPS) for the quarter, beating the consensus estimate of $-0.23 by $0.1. The company posted an earnings surprise of 43.5%.

Currently Histogenics Cp Cmn (NASDAQ:HSGX)’s shares owned by insiders are 16.49%, whereas shares owned by institutional owners are 47.9%. However the six-month change in the insider ownership was recorded 0.03%, as well as three-month change in the institutional ownership was recorded -0.42%.

Histogenics Cp Cmn (NASDAQ:HSGX)’s trailing twelve month revenues are $0, whereas its price to sales ratio for the same period is 0. Its book value per share for the most recent quarter is $-0.82 while its price to book ratio for the same period is 0, as for as the company’s cash per share for the most recent quarter is $0.18, however its price to cash per share ratio for the same period is 3.03. The stock has 5 year expected PEG ratio of 0 whereas its trailing twelve month P/E ratio is 0.